Microsatellite Instability Status form Cell free DNA in Cancer Patients
- Conditions
- Health Condition 1: null- Coloon cancer Rectal cancer Stomach cancer endometrial cancer
- Registration Number
- CTRI/2018/07/014730
- Lead Sponsor
- exent Bio Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Age 18 years or older
1 Able to understand and grant informed consent
2 Able to have their blood drawn at enrolment
3 Registration and blood draw should be before surgery for patients with surgically resectable disease or before initiation of active therapy with non resectable disease
4 Prior therapy is allowed as long as there is locally advanced or metastatic measurable and/or non measurable but evaluable disease progression orrecurrence since last treatment
5 Availability of tissue sections or tumour containing tissue block either from a previously obtained or planned surgery.
6 Biopsy confirmed adenocarcinoma of the colon or rectum, endometrial cancers, or adenocarcinoma of the stomach including gastroesophageal adenocarcinomas
Unable to grant informed consent or comply with all study procedures
Only non measurable or non evaluable disease at the time of blood collection
Non-malignant tumors
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 100% Quantification of MSI content in cfDNA and tissueTimepoint: Six Months
- Secondary Outcome Measures
Name Time Method The MSI status of the study population will be summarised using descriptive statisticsTimepoint: Six Months